Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

There are two main types of pancreatic cancer: exocrine pancreatic cancer, which accounts for the majority of cases and arises from the cells that produce enzymes for digestion, and endocrine pancreatic cancer, which is less common and originates from the hormone-producing cells of the pancreas. The most common type of exocrine pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which arises from the cells lining the ducts of the pancreas.

The risk factors for pancreatic cancer include advanced age, smoking, a family history of pancreatic cancer, obesity, chronic pancreatitis, diabetes, and certain genetic mutations. Pancreatic cancer may also metastasize to other organs, such as the liver, lungs, and abdominal lining, which further complicates treatment options.

Treatment for pancreatic cancer may involve a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. However, due to the aggressive nature of pancreatic cancer and its tendency to be diagnosed at advanced stages, the success of treatment options is often limited. Palliative care may also be an important component of management to improve quality of life for patients with advanced pancreatic cancer.

Liquid biopsy is a non-invasive diagnostic technique that involves the analysis of circulating tumor cells and genetic material released by tumor cells, such as circulating tumor DNA (ctDNA), in a patient’s blood or other body fluids. It has emerged as a promising approach for detecting genetic mutations and alterations associated with cancer, providing valuable information for personalized cancer care, monitoring treatment response, and detecting minimal residual disease. Liquid biopsy has the potential to revolutionize cancer diagnostics and management by offering a less invasive and more accessible method for detecting and monitoring cancer-related changes in the blood.